(ALDX) Aldeyra Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALDX) Aldeyra Therapeutics, Inc. Complete Analysis Pack
Aldeyra Therapeutics: Business Model Canvas at a Glance
Unlock the strategic logic behind Aldeyra Therapeutics, Inc.’s business model. This concise Business Model Canvas shows how the company creates value, builds partnerships, and pursues growth in a highly competitive biotech market. Get the full version for a deeper, ready-to-use breakdown for investors, analysts, and strategists.
Partnerships
Madrigal Pharmaceuticals ADX-1612 license
Madrigal Pharmaceuticals is the stated licensing partner for ADX-1612, giving Aldeyra Therapeutics access to a chaperome-inhibitor program for inflammatory diseases. The deal broadens Aldeyra Therapeutics’ pipeline beyond its core ophthalmology assets, reducing concentration risk; as of 2025 filings, Aldeyra Therapeutics still leaned heavily on ophthalmology R&D and had no reported commercial product revenue.
Clinical trial sites and investigators
Clinical trial sites and investigators are core partners for Aldeyra Therapeutics, Inc., because its Phase II and Phase III work in ophthalmology and systemic disease depends on them to enroll patients, run protocols, and capture endpoint data. This matters for reproxalap, ADX-629, and ADX-2191, where site performance can determine readouts in multi-center studies across hundreds of patients.
Contract research organizations
Aldeyra Therapeutics uses contract research organizations to handle monitoring, data management, and trial operations, which matters as its multi-asset pipeline pushes several late-stage studies at once. CRO support helps run parallel Phase 3 work across indications, adding capacity without building a large in-house trial team.
Contract manufacturing organizations
Contract manufacturing organizations are critical to Aldeyra Therapeutics, Inc. because ADX-2191, reproxalap, and ADX-629 each need reliable drug substance and drug product supply for clinical work and possible future launch. For a 3-program pipeline, CMOs also keep fixed capital low, which matters for a development-stage company.
- 3 programs need scalable supply
- Supports clinical and commercial use
- Lowers fixed-capital burden
- Helps keep manufacturing flexible
Regulatory and advisory partners
Aldeyra Therapeutics, Inc. depends on FDA and other regulatory touchpoints because it is still clinical-stage, with 0 product sales in FY2025. Scientific advisors and ophthalmology experts help refine endpoints for dry eye, allergic conjunctivitis, and retinal programs, which supports trial design, approval strategy, and label wording.
- Regulators guide trial design
- Experts shape efficacy endpoints
- Partnerships support labeling
Partnerships Power Aldeyra’s Pipeline in FY2025
Aldeyra Therapeutics, Inc. relies on licensing, trial, manufacturing, and regulatory partners to fund and run its pipeline. In FY2025, it still had 0 product sales, so these ties were key to advancing reproxalap, ADX-629, and ADX-2191 without heavy fixed cost.
| Partner | Role |
|---|---|
| Madrigal | ADX-1612 license |
| CROs/CMOs | Trials and supply |
| FDA/advisers | Design and approval |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Aldeyra Therapeutics, mapping its biotech strategy, customers, channels, value proposition, and key resources.
Customizable Excel Spreadsheet
Quickly maps Aldeyra Therapeutics’ pain-point reliever strategy in a concise, one-page business model snapshot.
Reference Sources
Aldeyra Therapeutics, Inc. Reference Sources provide a credible trail of evidence that speeds due diligence and supports smarter decisions.
Activities
RASP-modulator research and discovery
Aldeyra Therapeutics, Inc. centers RASP-modulator research on reactive aldehyde species, with Reproxalap and ADX-629 as its main assets in development. Discovery work also feeds new indications and next-generation compounds, so the platform is meant to turn one chemistry base into multiple shots on goal.
Phase II and Phase III clinical development
Aldeyra Therapeutics, Inc. centers its value creation on Phase II and Phase III clinical development, running late-stage human studies in ocular and systemic immune-mediated disorders. Reproxalap is in Phase III, ADX-629 is in Phase II, and ADX-2191 spans Phase III and Phase II programs, so clinical execution is the main driver of pipeline value.
Regulatory filing preparation
For Aldeyra Therapeutics, Inc., regulatory filing preparation means building IND amendments, safety updates, and eventual NDA/BLA-style packages around each trial readout, so every data set can support approval and labeling. As a development-stage biotech, this work is a gatekeeper activity: one weak filing can slow or block a program from moving from Phase 2/3 data to FDA review.
Clinical and nonclinical manufacturing management
Aldeyra Therapeutics, Inc. must keep GMP supply moving for study drug and stability work across oral and ophthalmic programs, because manufacturing control is what keeps trials supplied and the launch path ready. In 2024, the Company posted a net loss of about $49 million, so tight batch oversight and low-waste planning matter for cash use.
That same activity helps bridge clinical execution and commercialization readiness, with the main risk sitting in supply continuity and release timing for regulated product lots.
- Secure GMP study-drug supply
- Run stability programs on time
- Oversee oral and ophthalmic batches
- Support trials and launch prep
Business development and licensing
Aldeyra uses business development to add assets without bearing all R&D costs, as it did with ADX-1612, a licensed oncology candidate. The model can bring partner-funded development, upfront or milestone cash, and future royalties, which helps offset Aldeyra’s internal pipeline spend and extends runway.
- Licensing adds assets like ADX-1612.
- Partners can fund development.
- Milestones and royalties can follow.
- It reduces net R&D burden.
Aldeyra Advances 3 Late-Stage Programs Amid $49M 2024 Loss
Aldeyra Therapeutics, Inc. key activities are late-stage clinical trials, with Reproxalap in Phase III, ADX-629 in Phase II, and ADX-2191 in Phase II/III programs. It also runs GMP supply, stability work, and regulatory filings, while licensing can add partner-funded assets like ADX-1612.
| Activity | Data |
|---|---|
| Pipeline execution | 3 active programs |
| 2024 net loss | About $49m |
Full Document Unlocks After Purchase
Business Model Canvas
This Aldeyra Therapeutics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. What you see here is a direct snapshot of the final file, with the same structure, content, and formatting. Once you buy, you’ll get full access to this same ready-to-use document.
Resources
Reproxalap clinical asset
Reproxalap is Aldeyra Therapeutics, Inc.’s lead asset and the main near-term value driver: a reactive aldehyde species modulator in Phase III for dry eye disease and allergic conjunctivitis, with 2 late-stage indications tied to its revenue outlook. Its clinical readouts and regulatory path are central to valuation because the asset still anchors the pipeline.
ADX-629 oral RASP modulator
ADX-629 is Aldeyra Therapeutics, Inc.’s first-in-class oral RASP modulator, now in Phase II testing for psoriasis, asthma, and COVID-19. The oral dose form broadens the platform beyond ophthalmology and could support a larger, easier-to-use systemic market than eye-drop-only programs.
ADX-2191 ophthalmic and retinal program
ADX-2191 is Aldeyra Therapeutics’ dihydrofolate reductase inhibitor for retinal and rare-eye disease, in Phase 3 for proliferative vitreoretinopathy and Phase II for retinitis pigmentosa and primary vitreoretinal lymphoma. This expands Aldeyra beyond inflammation into a market with few approved options, while the company reported $47.3 million in cash, cash equivalents, and marketable securities at March 31, 2025.
ADX-1612 license asset
ADX-1612 is a licensed, 1-asset intellectual property input from Madrigal Pharmaceuticals that Aldeyra Therapeutics, Inc. uses to pursue inflammation programs. The chaperome inhibitor profile gives Aldeyra Therapeutics, Inc. a non-dilutive development resource, but value still depends on clinical progress and any milestone or royalty terms in the license.
- Licensed from Madrigal Pharmaceuticals
- Inhibits the chaperome
- Targets inflammatory diseases
Scientific IP and Massachusetts headquarters
Aldeyra Therapeutics was founded in 2004 and adopted its current name in March 2014. Its Lexington, Massachusetts headquarters anchors the firm’s scientific IP, clinical know-how, and management base, which are the core resources behind its drug pipeline and execution.
- Founded in 2004
- Renamed in March 2014
- Headquartered in Lexington, Massachusetts
- Core assets: IP, clinical know-how, management
Aldeyra’s Pipeline and Cash Back Its Next Clinical Milestones
Aldeyra Therapeutics, Inc.’s key resources are its clinical-stage pipeline, especially reproxalap, ADX-629, and ADX-2191, plus its licensed ADX-1612 platform and in-house RASP expertise. As of March 31, 2025, the company held $47.3 million in cash, cash equivalents, and marketable securities, which supports ongoing trials but still leaves execution tied to clinical readouts.
| Key resource | Latest status | Value driver |
|---|---|---|
| Reproxalap | Phase III | Lead asset |
| ADX-629 | Phase II | Systemic expansion |
| ADX-2191 | Phase 3 / Phase II | Rare-eye pipeline |
| Cash | Mar. 31, 2025 | $47.3 million |
Value Propositions
Novel RASP-based mechanism
Aldeyra Therapeutics, Inc.’s RASP platform targets reactive aldehyde species, an upstream driver of inflammation that differs from standard anti-inflammatory drug classes. This science underpins multiple pipeline assets and has already supported late-stage work, including 3 clinical-stage programs built on the same mechanism.
Late-stage dry eye and allergy therapy
Reproxalap targets dry eye disease and allergic conjunctivitis, two large recurring-care markets: dry eye affects about 38 million U.S. adults, and allergic conjunctivitis is a common seasonal and year-round condition. As a Phase III asset, it gives Aldeyra Therapeutics, Inc. a near-term shot at commercialization in a market where patients often need repeated treatment, not a one-time cure.
First-in-class oral immune-modulation option
ADX-629 is an oral immune-modulation candidate aimed at systemic immune-mediated diseases, broadening Aldeyra Therapeutics, Inc.’s reach beyond injectable care. That matters in big markets: psoriasis affects about 125 million people worldwide, and asthma about 262 million, so a pill could improve convenience, adherence, and access versus shots.
Rare-eye and retinal disease coverage
ADX-2191 extends Aldeyra Therapeutics, Inc. into high-need rare eye disease markets: proliferative vitreoretinopathy, retinitis pigmentosa, and primary vitreoretinal lymphoma. Retinitis pigmentosa affects about 1 in 3,500 to 1 in 4,000 people, and PVR complicates up to 10% of retinal detachment repairs, so the program reaches patients with few options.
- Targets three hard-to-treat retinal diseases
- Expands beyond anterior-segment disease
- Addresses rare, high-unmet-need patients
Multi-asset pipeline in immune-mediated disease
Aldeyra Therapeutics, Inc. has 3 active therapeutic programs plus 1 licensed inflammatory-disease asset, giving it 4 shots on goal across ocular and systemic immune-mediated disease. That mix reduces reliance on one trial readout and spreads risk across multiple clinical paths.
- 3 active programs
- 1 licensed asset
- Ocular and systemic reach
- Lower single-asset risk
Aldeyra’s RASP Platform Targets High-Need Eye and Immune Diseases
Aldeyra Therapeutics, Inc. centers its value proposition on the RASP platform, which targets reactive aldehyde species upstream of inflammation, supporting 4 shots on goal across ocular and systemic immune disease. Reproxalap, ADX-629, and ADX-2191 address recurring-care and rare, high-unmet-need markets with clear convenience and access gaps.
| Asset | Value prop | Need |
|---|---|---|
| Reproxalap | Phase III eye drop | Dry eye, allergic conjunctivitis |
| ADX-629 | Oral immune modulator | Systemic disease |
| ADX-2191 | Rare-eye candidate | PVR, RP, PVRL |
Customer Relationships
Specialist-led physician engagement
Aldeyra Therapeutics, Inc. relies on specialist-led physician engagement, with key prescribers in ophthalmology, retina, and allergy or pulmonary care. Relationships are built through trial data, medical education, and investigator outreach, which is the standard model for specialty biotech drugs.
Clinical trial participant support
Clinical trial participant support at Aldeyra Therapeutics, Inc. centers on informed consent, visit scheduling, and safety follow-up for Phase II and Phase III patients, all run by clinical sites under protocol. Strong retention matters because even small dropout rates can weaken endpoint quality and delay readouts.
Medical affairs and scientific exchange
Aldeyra Therapeutics, Inc. uses medical affairs to turn peer-reviewed and late-stage clinical data into clear talks on mechanism, efficacy, and safety for eye specialists before and after approval. This keeps scientific exchange tied to evidence from 3 core areas: study design, endpoints, and safety, which helps build trust and support adoption.
Partner relationship management
Partner relationship management at Aldeyra Therapeutics, Inc. centers on tight governance for licensing and collaboration partners, with regular reporting on milestones, development plans, and IP duties. The Madrigal agreement makes this direct partner communication a core customer tie, since Aldeyra must keep the collaboration aligned on clinical progress, payments, and rights.
- Govern milestones and reporting
- Track development plan changes
- Protect IP and contract rights
- Maintain direct Madrigal communication
Post-approval support model
If approved, Aldeyra Therapeutics, Inc. would likely run a high-touch post-approval model with nurse support, adverse-event reporting, and reimbursement help to improve access and adherence. That matters in chronic, specialist-managed eye and immune diseases, where U.S. dry eye alone affects about 16 million adults.
- Patient support for onboarding
- Safety reporting for ongoing monitoring
- Reimbursement help to reduce delays
- High-touch care for chronic use
Data-Led Eye Care: Aldeyra’s High-Touch Model
Aldeyra Therapeutics, Inc. keeps customer ties tight and scientific: specialist doctors, trial sites, and partners get frequent data updates, protocol support, and milestone reporting. If approved, the model shifts to high-touch patient support and reimbursement help for chronic eye disease, where dry eye affects about 16 million U.S. adults.
| Customer | Need | Metric |
|---|---|---|
| Specialists | Data-led adoption | Late-stage trial readouts |
| Patients | Adherence support | 16 million dry eye adults |
| Partners | Governance | Milestone reporting |
Channels
Clinical trial sites
Clinical trial sites are Aldeyra Therapeutics, Inc.’s main channel for Phase II and Phase III work, where investigator-led teams enroll patients and collect endpoint data. This model links the Company with specialist prescribers and the exact patient groups needed for late-stage ophthalmology and inflammation trials.
Specialist physician offices
Specialist physician offices are the main channel for diagnosis and treatment start at Aldeyra Therapeutics, Inc., because ophthalmology and retina practices are where dry eye and retinal patients are seen first. Allergy and pulmonary specialists also matter for future immune-mediated systemic programs, since these offices handle the patients most likely to need specialist-led prescribing.
Hospital and academic medical centers
Aldeyra Therapeutics, Inc. uses hospital and academic medical centers for its vitreoretinal lymphoma and proliferative vitreoretinopathy programs because these are rare, high-complexity eye diseases that need retina specialists and advanced imaging. These sites also matter for trial enrollment and early adoption, since academic centers treat many of the hardest cases and often lead evidence-based care.
Licensing and partnering channels
Licensing and partnering channels let Aldeyra Therapeutics, Inc. turn pipeline assets into non-dilutive capital, so growth does not depend only on share issuance. The ADX-1612 license shows how external partners can carry an asset forward while Aldeyra keeps focus on R&D and preserves cash.
- Non-dilutive value from partners
- ADX-1612 is a live example
- Extends reach without big sales force
Regulatory and scientific communications
Aldeyra Therapeutics, Inc. uses FDA filings, conference posters, and journal papers to show clinical data because it had no product sales in its latest reported year, so these messages carry the whole story. In a development-stage biotech, each submission can shift physician trust and investor sentiment fast.
- FDA updates signal trial progress
- Posters spread data to doctors
- Publications support credibility
Why Aldeyra’s Reach Runs Through Trials, Specialists, and Partnerships
Clinical trial sites, specialist offices, and academic centers are Aldeyra Therapeutics, Inc.’s main channels, because the Company had no product sales in its latest reported year and still relies on data readouts to reach doctors and investors. Partnering is a smaller but real channel: ADX-1612 shows how licensing can move an asset forward without a big sales force.
| Channel | Latest data |
|---|---|
| Product sales | 0 |
| Lead partner example | ADX-1612 license |
| Core reach | Trials, specialists, academics |
Customer Segments
Patients with dry eye disease
Patients with dry eye disease are Aldeyra Therapeutics, Inc.'s core target for reproxalap, a late-stage therapy aimed at a chronic condition that can affect an estimated 16 million U.S. adults. Because symptoms often need ongoing care, this segment offers repeat-treatment demand and a large addressable market.
Patients with allergic conjunctivitis
Aldeyra Therapeutics, Inc. is studying reproxalap for allergic conjunctivitis, which creates a seasonal, recurring use case tied to pollen peaks and repeat treatment demand. Patients in this segment are usually managed by eye-care specialists, mainly ophthalmologists and optometrists.
Patients with psoriasis and asthma
Psoriasis affects about 125 million people worldwide, and asthma about 262 million, making both large, long-term care markets. ADX-629’s oral immunomodulator profile fits patients with systemic immune-mediated disease who need chronic, convenient therapy.
Patients with retinal and rare eye diseases
ADX-2191 serves patients with proliferative vitreoretinopathy, retinitis pigmentosa, and primary vitreoretinal lymphoma, all rare and hard-to-treat eye diseases. Retinitis pigmentosa affects about 1 in 3,500 people, while PVR complicates roughly 5%-10% of retinal detachment repairs, so care is usually routed to tertiary eye centers.
These segments are small, specialized, and diagnosis-heavy, which makes access and referral speed critical. Primary vitreoretinal lymphoma is especially rare and often managed at academic ophthalmology centers.
- Rare, specialist-led patient pool
- Mostly treated in tertiary centers
- High unmet need, low competition
Physicians, payers, and specialty care institutions
Aldeyra Therapeutics, Inc. sells through prescribing physicians, while payers decide access, formulary status, and out-of-pocket cost. In rare disease care, specialty clinics and hospitals can make or slow adoption, so site-of-care matters as much as the prescription.
- Physicians drive prescribing
- Payers control access
- Hospitals shape adoption
Aldeyra Targets Large Chronic Eye and Immune Disease Markets
Aldeyra Therapeutics, Inc. targets patients with dry eye disease and allergic conjunctivitis for reproxalap, plus rare retinal and inflammatory diseases through ADX-2191 and ADX-629. The core customers are chronic eye-care patients, specialist-treated rare-disease patients, and immune-mediated disease patients needing repeat or long-term care.
| Segment | Key data |
|---|---|
| Dry eye disease | ~16M U.S. adults |
| Psoriasis | ~125M worldwide |
| Asthma | ~262M worldwide |
| Retinitis pigmentosa | ~1 in 3,500 |
Cost Structure
Clinical trial expenses
Clinical trial expenses are Aldeyra Therapeutics, Inc.’s biggest cash drain, because Phase II and Phase III studies pay for patient recruitment, monitoring, labs, and site fees. In biotech, a single late-stage trial can cost $20 million to $100 million+, and running multiple studies at once can quickly push annual R&D spend higher.
Research and discovery spending
Research and discovery spending is Aldeyra Therapeutics, Inc.’s core pipeline cost, funding assay work, preclinical studies, and translational science for next-step compounds and new uses. In 2025, research and development stayed its largest operating cost, at the center of pipeline sustainment and future indication expansion.
Manufacturing and supply costs
Manufacturing and supply costs stay high because Aldeyra Therapeutics, Inc. must make drug substance and drug product under cGMP, then pay for stability, packaging, and release testing. Oral and ophthalmic lines also need separate supply chains, so even small batch runs can add planning and inventory costs.
General and administrative overhead
Aldeyra Therapeutics, Inc. general and administrative overhead covers finance, legal, HR, corporate admin, IP management, and investor relations. For a public biotech, this also includes headquarters and executive pay; the cost base stays high even before product sales.
Key drivers: SEC reporting, patent upkeep, board work, and public-market communication.
- Finance and legal
- HR and admin
- IP and investor relations
- HQ and executives
Regulatory and quality assurance expenses
Regulatory and quality assurance spending for Aldeyra Therapeutics, Inc. covers FDA and EMA submissions, GxP compliance, and quality systems that support late-stage ophthalmology assets like reproxalap. These costs typically step up near approval, when documentation, audit readiness, and lot-release controls become critical.
- Higher spend near NDA/BLA filing
- Required for clinical-to-commercial handoff
- Quality systems reduce approval risk
Aldeyra’s 2025 Cash Burn: R&D and Trials Lead the Way
In 2025, Aldeyra Therapeutics, Inc. spent mainly on R&D, regulatory work, and public-company overhead, while clinical trials remained the biggest cash use. This cost mix is typical for a late-stage biotech: high spend now, no product revenue yet.
| 2025 cost driver | Impact |
|---|---|
| R&D | Largest operating cost |
| Trials | Phase II/III spend |
| G&A | SEC, legal, HQ |
Revenue Streams
Future product sales
If approved, Aldeyra Therapeutics, Inc.'s three lead assets—reproxalap, ADX-629, and ADX-2191—could turn into direct drug sales, the long-term core of revenue. Specialty ophthalmology and immune-mediated disease drugs often carry premium pricing, and even 1 approved niche product can shift a company from zero product revenue to recurring sales.
License and collaboration income
Aldeyra Therapeutics, Inc. uses license and collaboration income, with the ADX-1612 deal showing it can monetize assets before launch. Upfront fees and partner-funded work can help finance R&D, and in FY2025 this income stream still matters because it cuts dependence on product-sale timing.
Development milestones
Development milestones are a key revenue stream for Aldeyra Therapeutics, Inc.: biotech license deals often pay at Phase 2/3 completion, NDA filing, FDA approval, and first commercial launch. These checks can run from low millions to tens of millions of dollars, and they matter most before any product sales start.
Royalties on partnered assets
Royalty income from licensed programs would be high-margin because Aldeyra Therapeutics, Inc. does not need to fund manufacturing or field sales. In the latest reported period, royalty revenue was $0, so ADX-1612 is the clearest path to future upside if a partner commercializes it.
- High-margin, low-cost revenue
- Current royalty revenue: $0
- ADX-1612 is the main option
Grant and non-dilutive funding
Aldeyra Therapeutics, Inc. can use grant and other non-dilutive funding to help pay for rare-disease and early-stage R&D, which can ease pressure on operating cash and reduce reliance on equity sales. This matters when drug programs are long-dated and capital heavy.
- Funds early, high-risk work
- Preserves shareholder capital
- Supports rare-disease programs
Aldeyra’s FY2025 Revenue Still Depends on Partnerships, Not Sales
Aldeyra Therapeutics, Inc.'s revenue is still pre-commercial in FY2025, so sales depend mainly on collaboration cash, milestones, and possible royalties, not product sales yet. Royalty revenue was $0, while ADX-1612 remains the clearest partner-led upside.
| Stream | FY2025 |
|---|---|
| Product sales | 0 |
| Royalties | 0 |
| Collaborations/milestones | Non-dilutive |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.